Filing Details
- Accession Number:
- 0001172661-19-000630
- Form Type:
- 13G Filing
- Publication Date:
- 2019-02-14 10:17:41
- Filed By:
- Polar Capital
- Company:
- Stemline Therapeutics Inc (NASDAQ:STML)
- Filing Date:
- 2019-02-14
- SEC Url:
- 13G Filing
Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Polar Capital LLP | 2,902,666 | 0 | 2,902,666 | 0 | 2,902,666 | 9.13% |
UNITED STATES
SECURITIES AND EXCHANGE
COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Stemline Therapeutics, Inc.
| (Name of Issuer) |
|
Common stock, $0.0001 par value per share |
| (Title of Class of Securities) |
85858C107 |
| (CUSIP Number) |
|
|
| December 31, 2018 |
| (Date of Event Which Requires Filing of this Statement) |
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
x Rule 13d-1(b)
o Rule 13d-1(c)
o Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
| CUSIP No. 85858C107 | SCHEDULE 13G | Page 6
of 6 Pages |
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
Date: February 14, 2019
| POLAR CAPITAL LLP | |||
| By: | Nicholas Farren | ||
| Name: | Nicholas Farren | ||
| Title: | Head of Operations | ||